ROCKVILLE, Md., March 13, 2018 /PRNewswire/ -- ExeGi Pharma LLC, a company focused on developing and
The formulation in Visbiome Vet contains an eight-strain proprietary probiotic blend that has recently been studied in several canine GI disorders, with two clinical trials published in the last 12 months. Visbiome Vet is the identical formulation to Visbiome®, a human medical food that has been the subject of over 60 clinical trials.
"Serious gastrointestinal conditions in dogs are often linked to alterations in the GI bacterial community, commonly known as the gut microbiome," said Dr. Jan Suchodolski, PhD, DACVM at Texas A&M University. "Visbiome Vet has been shown in a variety of trials to help normalize gut health."
Visbiome Vet contains 112.5 billion live bacteria per dosage, a potency that far exceeds other conventional veterinary probiotics. The product, only available to veterinarians and veterinary pharmacies, is packaged conveniently for veterinary applications. Visbiome Vet is shipped and stored only under refrigerated conditions to ensure maximum product potency.
"Over the last year we have been overwhelmed by pet owners telling us about the tremendous results they were experiencing using our human Visbiome product with their dogs," said Marc Tewey, CEO of ExeGi Pharma. "We are pleased to finally bring this high potency probiotic formulation to the veterinary community with Visbiome Vet."
Visbiome Vet is available exclusively to veterinarians and veterinary pharmacies. For more information, please visit visbiomevet.com or exegipharma.com.
About ExeGi PharmaExeGi Pharma LLC, is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. ExeGi's team leverages scientific expertise in the field of microbiome science to deliver novel, clinically-supported live biotherapeutic and probiotic treatments for a variety of unmet medical needs. ExeGi is headquartered in Rockville, MD.
View original content:http://www.prnewswire.com/news-releases/exegi-pharma-launches-high-potency-veterinary-probiotic-to-help-manage-gi-tract-illnesses-in-dogs-300612722.html
SOURCE ExeGi Pharma LLC
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All